Colman Rebecca, Singer Lianne G, Barua Reeta, Downar James
1 Division of Respirology, University of Toronto , Toronto, Ontario, Canada .
J Palliat Med. 2015 Mar;18(3):266-9. doi: 10.1089/jpm.2014.0167. Epub 2014 Aug 27.
Lung transplantation (LT) recipients carry a high symptom burden. Palliative Care (PC) is a field of medicine focused on symptom control and psychosocial support, but transplant recipients are often referred to PC very late in the disease course, if at all. In our institution, the LT service has increasingly consulted PC to co-manage LT recipients with end-stage graft dysfunction or other terminal conditions. We present the characteristics, PC interventions used, and outcomes of these patients.
We conducted a single-center, retrospective, cohort study of LT recipients referred for PC consultation between January 2010 and May 2012. We collected patient demographics, timing and location of PC consultation, PC interventions, and patient outcomes.
Twenty-four patients met the inclusion criteria. Sixteen (67%) had chronic allograft dysfunction. Reasons for referral were dyspnea (42%), end-of-life planning (42%), pain (29%), cough (4%), anxiety (4%), and depression (4%). Referral was made a median of 3.2 (range, 0.2 to 18) years from transplant and a median 14 days (range, 0 to 227 days) from death. Eighty-three percent of consultations occurred >48 hours from time of death. Ninety-two percent of patients were prescribed opioids over their course of treatment. Among the 12 (50%) who died in our center, 10 (83%) were receiving comfort medications. Eight patients (33%) initially requested full resuscitation at the time of PC consultation, but seven of these patients (or their surrogates) later agreed to a do not resuscitate (DNR) order; the eighth was still alive at last follow-up. No patient in this study received cardiopulmonary resuscitation (CPR) at the time of death.
LT recipients referred for PC co-management typically receive comfort medications and avoid the aggressive end-of-life care usually reported for this population. The effect of PC interventions on patient quality of life requires further study.
肺移植(LT)受者承受着较高的症状负担。姑息治疗(PC)是一个专注于症状控制和心理社会支持的医学领域,但移植受者往往在疾病进程的很晚阶段才被转介至姑息治疗,甚至根本没有被转介。在我们机构,肺移植团队越来越多地咨询姑息治疗团队,以共同管理患有终末期移植物功能障碍或其他终末期疾病的肺移植受者。我们介绍了这些患者的特征、所采用的姑息治疗干预措施及结果。
我们对2010年1月至2012年5月间被转介至姑息治疗咨询的肺移植受者进行了一项单中心、回顾性队列研究。我们收集了患者的人口统计学资料、姑息治疗咨询的时间和地点、姑息治疗干预措施及患者结局。
24名患者符合纳入标准。16名(67%)患有慢性移植物功能障碍。转介原因包括呼吸困难(42%)、临终规划(42%)、疼痛(29%)、咳嗽(4%)、焦虑(4%)和抑郁(4%)。转介时间中位数为移植后3.2年(范围0.2至18年),距死亡时间中位数为14天(范围0至227天)。83%的咨询发生在距死亡时间超过48小时。92%的患者在治疗过程中被开具了阿片类药物。在我们中心死亡的12名(50%)患者中,10名(83%)正在接受舒适护理药物治疗。8名患者(33%)在姑息治疗咨询时最初要求全力复苏,但其中7名患者(或其代理人)后来同意了“不要复苏”(DNR)医嘱;第8名患者在最后一次随访时仍存活。本研究中没有患者在死亡时接受心肺复苏(CPR)。
被转介至姑息治疗共同管理的肺移植受者通常会接受舒适护理药物治疗,并避免了通常报道的针对该人群的激进的临终护理。姑息治疗干预措施对患者生活质量的影响需要进一步研究。